Update on Binge Eating Disorder - 09/05/19

Doi : 10.1016/j.mcna.2019.02.003

Anna I. Guerdjikova, PhD, LISW ^a,^b,^⁎ , Nicole Mori, RN, MSN, APRN-BC ^a,^b, Leah S. Casuto, MD ^a,^b, Susan L. McElroy, MD ^a,^b
^a Lindner Center of HOPE, 4075 Old Western Row Road, Mason, OH 45040, USA
^b Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 4075 Old Western Row Road, Mason, OH 45040, USA

^∗Corresponding author. Department of Psychiatry and Behavioral Neuroscience, Lindner Center of HOPE, University of Cincinnati College of Medicine, 4075 Old Western Row Road, Mason, OH 45040.Department of Psychiatry and Behavioral NeuroscienceLindner Center of HOPEUniversity of Cincinnati College of Medicine4075 Old Western Row RoadMasonOH45040

Resumen

Binge eating disorder (BED) is the most common eating disorder and an important public health problem. Lifetime prevalence of BED in the United States is 2.6%. In contrast to other eating disorders, the female to male ratio in BED is more balanced. BED co-occurs with a plethora of psychiatric disorders, most commonly mood and anxiety disorders. BED is also associated with obesity and its numerous complications. Although BED is similar in men and women in presentation and treatment outcomes, there are some key neurobiological differences that should be taken in consideration when personalizing treatment.

El texto completo de este artículo está disponible en PDF.

Keywords : Binge eating disorder, Female binge eating, Treatment, Gender, Sex differences, Eating dysregulation

Esquema

Key points

Binge eating disorder

Historical overview of binge eating disorder and other eating disorders

Overview of psychiatric and medical comorbidities of binge eating disorder

Binge eating disorder in women versus binge eating disorder in men

Neurobiology of binge eating disorder in women

Medical comorbidity of binge eating disorder in women

Treatment of binge eating disorder in women

Summary

This is an update of an article that first appeared in the Psychiatric Clinics of North America, Volume 40, Issue 2, June 2017.

N. Mori and L.S. Casuto have nothing to disclose. A.I. Guerdjikova is a consultant for Bracket and Avanir. S.L. McElroy has been a consultant to or member of the scientific advisory boards of Allergan, Avanir, Bracket, F. Hoffmann-La Roche Ltd., Mitsubishi Tanabe Pharma America, Myriad, Opiant, Shire, and Sunovion. She has been a principal or co-investigator on studies sponsored by Allergan, Avanir, Azevan, Brainsway, Marriott Foundation, Medibio, Myriad, Neurocrine, Novo Nordisk, Shire, and Sunovion. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, Ohio, and has received payments from Johnson & Johnson, which has exclusive rights under the patent.